Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein (Omicron BA.1 Variant) (Spike protein (Omicron BA.1))
- Target
- Spike protein (Omicron BA.1)
- Molecular classification
- Glycoprotein, Viral fusion protein, Receptor Ligand
01
Overview
The spike glycoprotein (S protein) of SARS-CoV-2 is a large, trimeric, class I fusion protein that mediates viral entry into host cells. The Omicron BA.1 variant features numerous mutations in this protein, particularly within the receptor-binding domain (RBD), which impact transmissibility and immune escape. It is the primary target for neutralizing antibodies and vaccines due to its critical role in infection and immune recognition.
- Other names
- SARS-CoV-2 Spike GlycoproteinS proteinOmicron BA.1 Spike protein
02
Mechanism of action
Neutralization of viral entry by blocking ACE2 binding or fusion
03
Biological functions
Viral entryReceptor bindingMembrane fusionImmune evasion
04
Disease associations
InfectionCOVID-19 pathogenesis
05
Safety considerations
Antibody-dependent enhancement (ADE)Immune escape due to mutationsOff-target effects of vaccines (rare)
06
Interacting drugs
Monoclonal antibodies (e.g., Sotrovimab, Evusheld)
2 more in the full profile.
07
Biomarkers
Spike protein antibody titersNeutralizing antibody titersViral loadSpike protein mutations
Beyond the preview
Go deeper on Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein (Omicron BA.1 Variant) (Spike protein (Omicron BA.1)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein (Omicron BA.1 Variant) (Spike protein (Omicron BA.1)).